Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
Healthcare
$1.24 +0.31%
+$0.00 today
- Market cap
- $96.38M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
52W Low $0.80High $4.85
Volume 1.66M
Average 2.44M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$20.37M
FY 2025 · Annual
Investing Cash Flow
-$801,000.00
FY 2025 · Annual
Financing Cash Flow
$35.85M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.73M) | (39.14M) |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M |
| Change in Working Capital | (6.64M) | (5.12M) | (14.1M) | (6.81M) | 6.58M |
| Accounts Receivables | (3.05M) | (6.66M) | (8.83M) | (3.73M) | 3.54M |
| Inventory | (3.44M) | (2.59M) | (1.1M) | 3.15M | (395K) |
| Accounts Payables | 276K | (1.97M) | 2.03M | (1.99M) | (1.75M) |
| Other Working Capital | (415K) | 6.1M | (6.2M) | (4.25M) | 5.18M |
| Other Non-Cash Items | 918K | 1.14M | 2.93M | 11.86M | 1.87M |
| Operating Cash Flow | (27.98M) | (30.74M) | (32.04M) | (31M) | (20.37M) |
| Capital Expenditures | (2.35M) | (3.27M) | (2.37M) | (1.47M) | (801K) |
| Acquisitions (Net) | 0 | 0 | 0 | (2.55M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 324K | 0 | 0 | 0 | (31K) |
| Other Investing Activities | (7.81M) | 10M | 1.05M | 1.61M | 31K |
| Investing Cash Flow | (9.84M) | 6.73M | (1.32M) | (2.41M) | (801K) |
| Debt Repayment | 0 | 0 | 23.8M | (2.52M) | 9.62M |
| Common Stock Issued | 80.97M | 0 | 0 | 0 | 26.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.03M | 207K | (1.1M) | (4.29M) | (594K) |
| Financing Cash Flow | 83.01M | 207K | 22.7M | (6.81M) | 35.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.18M | (23.8M) | (10.66M) | (40.22M) | 14.68M |
| Free Cash Flow | (30.34M) | (34.01M) | (34.41M) | (32.46M) | (21.18M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.1M
+ D&A$3.5M
+ Stock-Based Comp$6.8M
+ Deferred Tax$0
+ Working Capital$6.6M
+ Other Non-Cash$1.9M
= Operating Cash Flow-$20.4M
- Capex-$801.0K
= Free Cash Flow-$21.2M
Analysis
FY2025 free cash flow is -$21.2M. FCF conversion is 54.1% of net income. Operating cash flow was -$20.4M, with capex of -$801.0K. The largest bridge item is Stock-Based Comp at $6.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| 8-K/A | 8-K/A filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 10, 2026 |
Does STIM generate free cash flow?
Neuronetics, Inc. (STIM) generated -$21.18M of free cash flow in fiscal 2025.
How much operating cash flow does STIM produce?
Operating cash flow was -$20.37M, before capital expenditures of $801,000.00.
Continue the stock analysis
Jump to another research area for this company.